cardiovascular benefits of glp 1 The Many GLP-1 Drugs Updated evidence on cardiovascular and

This includes protein targets, meal timing strategies, foods to emphasize or avoid, and specific techniques for managing side effects

Cardiovascular symptoms to report within 24 hours : sustained resting heart rate above 100 bpm, home blood pressure readings above 150/95 mmHg on two consecutive measurements, dizziness on standing (suggesting orthostatic instability), or new-onset headache that differs from the patient's typical pattern

Your body was designed to grow, repair, and thrive

March is Endometriosis Awareness Month, and we want to hear YOUR stories about this under-discussed but surprisingly prevalent condition

ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer

Human data: caution The only human data published to date are extremely limited: a 2024 pilot trial in 12 patients with interstitial cystitis treated with 10 mg of BPC-157 injected into the bladder wall, and a 2026 pharmacokinetic study in two healthy subjects (one 58-year-old man and one 68-year-old woman) receiving intravenous BPC-157